Corvus Pharmaceuticals (CRVS) Gains from Investment Securities (2015 - 2026)

Corvus Pharmaceuticals' Gains from Investment Securities history runs 12 years deep, the most recent figure standing at $661334.0 for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 94.29% year-over-year to $661334.0; the TTM figure through Mar 2026 stood at $661334.0 (down 94.29% YoY), while the FY2025 annual figure was $14.0 million, up 17.54% from the prior year.
• Gains from Investment Securities was $661334.0 for Q1 2026 at Corvus Pharmaceuticals, down from $5.6 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $11.6 million in Q1 2025 to a low of -$2.0 million in Q2 2025.
• Historically, Gains from Investment Securities has averaged $1.1 million across 5 years, with a median of $203405.0 in 2022.
• The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities plunged 287.02% in 2024, then soared 40163.25% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at -$985000.0 in 2022, then retreated by 4.37% to -$1.0 million in 2023, then jumped by 328.31% to $2.3 million in 2024, then jumped by 138.45% to $5.6 million in 2025, then plunged by 88.18% to $661334.0 in 2026.
• The last three Gains from Investment Securities figures came in at $661334.0 (Q1 2026), $5.6 million (Q3 2025), and -$2.0 million (Q2 2025), per Business Quant data.